Shorts Target VIVUS (VVUS) Following January Pop; May be Entering 'Oversold' Territory
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
VIVUS (VVUS) Qsymia Prescriptions Jump 140%+ After Free Trial Program Starts
January 7, 2013 6:45 AM ESTVIVUS, Inc. (Nasdaq: VVUS) shares are looking to open higher Monday amid new Qsymia prescription data.
According to Bloomberg, Qsymia prescriptions jumped about 140 percent higher from 5,394 for the four-weeks ended October 26th to 12,978 in the four-week period ended December 21st. The pop came following commencement of its Free Trial program on November 19th through two certified pharmacies.
VIVUS said that a third pharma started the program in late December.
The October data was revised higher from an initial estimate of 4,904 prescriptions.
More color from an 8-K filing made... More
